SCHEMBL17385339

SCHEMBL17385339

OCc1cc2sc(N3CCCCC3)nc2s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 14/20 0.47
NPC1 O15118 12/20 0.47
SMN1; SMN2 Q16637 11/20 0.47
ALDH1A1 P00352 6/20 0.47
MAPT P10636 5/20 0.47
HPGD P15428 4/20 0.47
HSD17B10 Q99714 4/20 0.47
TP53 P04637 3/20 0.47
ALOX15 P16050 2/20 0.47
LMNA P02545 1/20 0.47
USP2 O75604 1/20 0.47
MAPK1 P28482 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.44
HTT P42858 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17385328 0.76 RAB9A (0.48) RAB9ANPC1SMN1; SMN2ALDH1A1MAPT
SCHEMBL17372954 0.75 RAB9A (0.43) RAB9ANPC1SMN1; SMN2ALDH1A1MAPT
SCHEMBL5039729 0.74 RAB9A (0.46) RAB9ANPC1SMN1; SMN2ALDH1A1MAPT
SCHEMBL18802955 0.74 NPC1 (0.50) RAB9ANPC1SMN1; SMN2ALDH1A1MAPT
SCHEMBL17385389 0.74 MAPT (0.50) RAB9ANPC1SMN1; SMN2ALDH1A1MAPT
SCHEMBL17385341 0.74 ALDH1A1 (0.51) RAB9ANPC1SMN1; SMN2ALDH1A1MAPT
SCHEMBL18802971 0.74 RAB9A (0.43) RAB9ANPC1SMN1; SMN2ALDH1A1MAPT
SCHEMBL22678273 0.72 HRH3 (0.41) RAB9ANPC1SMN1; SMN2ALDH1A1MAPT
SCHEMBL17385342 0.72 MAPT (0.53) RAB9ANPC1SMN1; SMN2ALDH1A1MAPT
SCHEMBL17385483 0.71 GAA (0.43) RAB9ANPC1SMN1; SMN2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220153756-A1 ANTI-INFECTIVE COMPOUNDS INSTITUT PASTEUR KOREA (KR) 2022-05-19 US disclosed
US-20170121349-A1 Anti-Infective Compounds INSTITUT PASTEUR KOREA (KR) 2017-05-04 US disclosed
WO-2015193506-A1 ANTI-INFECTIVE COMPOUNDS INSTITUT PASTEUR KOREA (KR) 2015-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220153756-A1 ANTI-INFECTIVE COMPOUNDS RABGGTB, ELANE, SERPINB1 RAB9A 1091/4885NPC1 402/4885SMN1; SMN2 4839/4885
US-20170121349-A1 Anti-Infective Compounds FNTB, LSS, PGLS RAB9A 594/4885NPC1 452/4885SMN1; SMN2 4810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.